Böhmer F D, Kraft R, Otto A, Wernstedt C, Hellman U, Kurtz A, Müller T, Rohde K, Etzold G, Lehmann W
Department of Cell Biology, Academy of Sciences of the German Democratic Republic, Berlin-Buch.
J Biol Chem. 1987 Nov 5;262(31):15137-43.
A polypeptide growth inhibitor purified from bovine mammary gland (mammary-derived growth inhibitor) has been shown to reversibly inhibit proliferation of mammary carcinoma cells at concentrations of about 10(-10) M. The carrier of inhibitory activity has been identified biochemically as an about 13-kDa polypeptide and chemically by elucidating the amino acid sequence. No homology to any of the hitherto structurally investigated growth inhibitors (transforming growth factor beta, interferons) has been observed. The data revealed extensive sequence homology of mammary-derived growth inhibitor to a family of low molecular mass hydrophobic ligand-binding proteins, among them a fatty acid-binding protein from rat heart, myelin P2, a differentiation associated protein in adipocytes (p422) and the cellular retinoic acid-binding protein. Interaction with as yet unknown hydrophobic ligands might play a functional role in the mechanism of growth inhibition excerted by mammary-derived growth inhibitor.
从牛乳腺中纯化出的一种多肽生长抑制剂(乳腺衍生生长抑制剂)已被证明,在浓度约为10^(-10) M时可可逆地抑制乳腺癌细胞的增殖。通过生化方法已将抑制活性的载体鉴定为一种约13 kDa的多肽,并通过阐明氨基酸序列进行了化学鉴定。未观察到与迄今在结构上研究过的任何生长抑制剂(转化生长因子β、干扰素)有同源性。数据显示,乳腺衍生生长抑制剂与一类低分子量疏水配体结合蛋白具有广泛的序列同源性,其中包括大鼠心脏中的一种脂肪酸结合蛋白、髓磷脂P2、脂肪细胞中的一种分化相关蛋白(p422)以及细胞视黄酸结合蛋白。与尚未明确的疏水配体相互作用可能在乳腺衍生生长抑制剂发挥生长抑制作用的机制中起功能性作用。